Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
337.38
+1.43 (+0.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
40
41
Next >
Why Vera Therapeutics Stock Soared by 22% This Week
January 12, 2024
Executive changes and a bullish analyst take combined to boost sentiment on the company.
Via
The Motley Fool
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
January 12, 2024
Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN).
Via
Chartmill
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
January 11, 2024
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.
Via
Benzinga
Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains
January 10, 2024
Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
How Is The Market Feeling About Amgen?
January 10, 2024
Via
Benzinga
Looking At Amgen's Recent Unusual Options Activity
January 09, 2024
Via
Benzinga
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
January 08, 2024
Via
Benzinga
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
January 10, 2024
Cramer shared his insights during his attendance at JPMorgan's healthcare conference,
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
10 Health Care Stocks With Whale Alerts In Today's Session
January 08, 2024
Via
Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
A Rough Start To 2024 What Might Be In Store For The Rest Of 2024?
January 07, 2024
The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year.
Via
Talk Markets
Looking At Amgen's Recent Unusual Options Activity
January 05, 2024
Via
Benzinga
Amgen's Options: A Look at What the Big Money is Thinking
December 28, 2023
Via
Benzinga
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
December 25, 2023
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
January 03, 2024
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.
Via
InvestorPlace
Is NASDAQ:AMGN a Good Fit for Dividend Investing?
December 22, 2023
Why AMGEN INC (NASDAQ:AMGN) is a Top Pick for Dividend Investors.
Via
Chartmill
Spotlight on Amgen: Analyzing the Surge in Options Activity
December 21, 2023
Via
Benzinga
Looking Into Amgen's Recent Short Interest
December 20, 2023
Via
Benzinga
Did Santa Claus Claus Leave Town A Day Early?
January 02, 2024
With the exception of the Dow, stocks are down hard to begin the new calendar year.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024
January 02, 2024
Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
January 01, 2024
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with.
Via
The Motley Fool
Topics
ETFs
Retirement
Exposures
Pension
Amgen Stock Sees Relative Strength Rating Improve To 74
December 29, 2023
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.
Via
Investor's Business Daily
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
December 29, 2023
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years
December 26, 2023
Amgen Inc (NASDAQ: AMGN) announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug
Via
Benzinga
Exposures
Product Safety
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
December 21, 2023
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."
Via
InvestorPlace
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
December 20, 2023
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.
Via
InvestorPlace
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
December 19, 2023
Amgen, Inc. (NASDAQ: AMGN) shares have been in focus amid developments in the AI-powered healthcare space.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.